Lymphoma Staging: — Ann Arbor, Lugano and What the Terms Mean

Stage IV means the lymphoma has reached organs outside the lymph node system. It does not automatically mean the worst outcome. Lymphoma — particularly Hodgkin lymphoma and some aggressive B-cell lymphomas — can respond well to treatment at Stage IV. The stage is one input into your haemato-oncologist's assessment, alongside the lymphoma subtype, your age, your general fitness, and early response to treatment. Stage alone does not determine prognosis. Ask your haemato-oncologist what Stage IV means specifically for your lymphoma subtype.

Lugano is built on the Ann Arbor framework. It uses the same stage numbers and suffixes, and layers PET-CT methodology on top. Many reports name both to make clear that the familiar Roman numeral system still applies and that the staging used current PET-CT criteria. If your report mentions both, it is not contradicting itself — Ann Arbor is the historical foundation and Lugano is the current international standard built on it.

Bulky disease refers to a lymphoma mass that meets a size threshold for being considered large. The threshold varies — different guidelines and different lymphoma subtypes use different definitions, and the Lugano classification also refined the bulkiness criterion compared to older Ann Arbor criteria. Your report should state the threshold it applied. Bulky disease can influence treatment decisions — for example, whether radiation is added alongside systemic therapy — independently of the overall stage number. Ask your haemato-oncologist directly whether the bulky designation affects your plan.

The stage assigned at diagnosis is fixed as a historical baseline. It is not updated to reflect treatment response. What changes during treatment is the response assessment, which uses a separate scoring system — in PET-avid lymphomas, this is typically reported using the Deauville five-point scale, not a revised stage number. Interim PET and end-of-treatment PET scans are response scans, not re-staging. Your haemato-oncologist interprets response scores in the context of your full clinical picture.

This grouping is used in many guidelines but varies by lymphoma type. For Hodgkin lymphoma, Stages I and II are generally called limited stage, and Stages III and IV advanced stage. For other subtypes, the clinically meaningful groupings differ. The presence of B symptoms or bulky disease can also shift a Stage II diagnosis into a treatment pathway more typical of advanced disease. Ask your haemato-oncologist which clinical group your specific diagnosis falls into and how that shapes the treatment plan.

B symptoms are a defined clinical finding — unexplained fever, drenching night sweats, and significant unexplained weight loss — and their presence adds the letter B to your stage because they are clinically significant. In some lymphoma types, particularly Hodgkin lymphoma, B symptoms have long influenced treatment decisions. What they mean for your situation depends on your lymphoma subtype, your stage, and other clinical factors. Tell your team about any of these symptoms even if they seem mild.